Stock Analysts’ Price Target Changes for May 28th (A, AFRM, ANF, APH, BBIO, BBWI, BNS, CARR, CF, COIN)
On May 28, analysts adjusted price targets across multiple stocks. Agilent’s target was cut by Wells Fargo ($165→$160) but raised by Barclays ($140→$145) and TD Cowen ($147→$155). Affirm’s target rose at Truist ($75→$80). Bath & Body Works saw mixed changes, while Salesforce targets were mostly lowered by several firms.
How this was made
The 30-second read
Why it matters
For each company, the immediate trading implication is sentiment/positioning around analyst consensus, not a new fundamental catalyst.
Market read
Useful for identifying which tickers saw fresh analyst attention on the day, but the lack of underlying rationale limits conviction.
What to watch
Net impact depends on which broker’s change is most widely held/covered and whether the target revisions reflect new information (not provided here).
Background
The article compiles analyst price-target changes and rating stances across many US-listed stocks for May 28.
Ticker impact
Agilent price targets were trimmed/raised by multiple firms, signaling shifting near-term expectations and sentiment around the stock.
Likely modest, sentiment-driven volatility rather than a directional fundamental repricing.
This is a price-target roundup without new company-specific fundamentals; direction depends on which broker notes dominate flows.
Affirm’s price target was boosted by Truist from $75 to $80, implying improved outlook versus prior expectations.
Small positive bias; watch for follow-through if other analysts echo the move.
Target changes can move shares at the margin, but the article provides no new earnings/metric catalyst.
Abercrombie & Fitch’s target was cut by Telsey from $125 to $115, indicating reduced expectations for ANF’s outlook.
Potential downside pressure if traders anchor to the lowered target.
No new operational data is provided; effect is likely limited to positioning around analyst sentiment.
Amphenol’s target increased by BNP Paribas Exane from $195 to $200, reflecting improved valuation assumptions for APH.
Slight upward drift possible, mostly sentiment/positioning related.
The article is purely target-level changes; without new fundamentals, impact should be modest.
BridgeBio Pharma’s target was raised by Morgan Stanley from $94 to $98, suggesting a more favorable risk/reward for BBIO.
Limited near-term upside bias; monitor for broader consensus changes.
Target changes alone rarely drive sustained moves without accompanying new trial/clinical or financial updates.
Bath & Body Works saw conflicting target moves (Wells Fargo cut; TD Cowen raise; others trim), indicating disagreement on BBWI’s trajectory.
Choppy/volatile tape possible; direction unclear without consensus net change.
The article lists several target adjustments but no new earnings/traffic/margin datapoint.
Bank of Nova Scotia’s target was increased by RBC from $98 to $117, a sizable uplift in valuation expectations for BNS.
Moderate positive bias possible if traders treat it as a consensus reset.
The article doesn’t provide the rationale or any new fundamental driver; also includes cross-listing context.
Carrier Global’s target was boosted by Morgan Stanley from $55 to $60, implying improved outlook for CARR.
Small positive drift likely, especially if other brokers align.
No new deal/earnings catalyst is included; impact should be limited to analyst-sentiment flows.
Market effects
Broad, cross-sector analyst target revisions can increase short-term dispersion and volatility, but without new fundamentals they’re unlikely to drive sector-wide repricing.
Primarily US-listed sentiment; one Canadian-linked name (BNS) may add minor cross-border trading interest.
Limited—this is a US analyst-target roundup rather than a global macro or geopolitical catalyst.
Counterpoint
Because this is only a price-target recap, the market may already discount these changes; follow-through may be weaker than traders expect.
Key entities
- market_signalAnalyst price targets
Broker-by-broker target trims/raises that can influence near-term trading and expectations.
